{"altmetric_id":12736242,"counts":{"readers":{"mendeley":4,"citeulike":0,"connotea":0},"total":{"posts_count":12},"twitter":{"unique_users_count":11,"unique_users":["KarenSweiss","satya_yadav","GarbineLizeaga","FarmaOnco","NatRevClinOncol","CancerWallonia","farmaSCQ","jai_mateo","elopmon","SCTNB","queizan"],"posts_count":12}},"selected_quotes":["Cu\u00e1ndo usar ruxolitinib en mielofibrosis: esplecnomegalia grave (+15cm post arco) o sintom\u00e1tica, o s\u00edntomas graves."],"citation":{"abstract":"Ruxolitinib is an oral JAK1\/JAK2 inhibitor approved for the treatment of patients with myelofibrosis (MF) based on the results of two randomized clinical trials. However, discordant indications were provided by regulatory agencies and scientific societies for selecting the most appropriate candidates to this drug. The European LeukemiaNet and the Italian Society of Hematology shared the aim of building evidence-based recommendations for the use of ruxolitinib according to the GRADE methodology. Eighteen patient-intervention-comparator-outcome profiles were listed, each of them comparing ruxolitinib to other therapies with the aim of improving one of three clinical outcomes: a) splenomegaly, b) disease-related symptoms, and c) survival. Ruxolitinib was strongly recommended for improving symptomatic or severe (>15\u2009cm below the costal margin) splenomegaly in patients with an IPSS\/DIPSS risk INT2 or high. Ruxolitinib was also strongly recommended for improving systemic symptoms in patients with a MPN10 score higher than 44, refractory severe itching, unintended weight loss not attributable to other causes or unexplained fever. Because of weak evidence, the panel does not recommend ruxolitinib therapy for improving survival. Also, the recommendations given above do not necessarily apply to patients who are candidates for allogeneic stem cell transplant.Leukemia accepted article preview online, 14 October 2016. doi:10.1038\/leu.2016.283.","altmetric_jid":"4f6fa4fa3cf058f610003008","authors":["M Marchetti","G Barosi","F Cervantes","G Birgeg\u00e5rd","M Griesshammer","C Harrison","R Hehlmann","J-J Kiladjian","N Kr\u00f6ger","M F McMullin","F Passamonti","A Vannucchi","T Barbui"],"doi":"10.1038\/leu.2016.283","endpage":"888","first_seen_on":"2016-10-18T20:04:38+00:00","funders":["niehs"],"issns":["1476-5551","0887-6924"],"journal":"Leukemia (08876924)","last_mentioned_on":1492877842,"links":["http:\/\/www.nature.com\/leu\/journal\/vaop\/naam\/abs\/leu2016283a.html","http:\/\/www.nature.com\/leu\/journal\/vaop\/ncurrent\/full\/leu2016283a.html?WT.mc_id=TWT_NatRevClinOncol","http:\/\/www.nature.com\/leu\/journal\/v31\/n4\/full\/leu2016283a.html"],"pmid":"27740634","pubdate":"2016-10-14T00:00:00+00:00","publisher":"Nature Publishing Group","publisher_subjects":[{"name":"Clinical Sciences","scheme":"era"},{"name":"Oncology And Carcinogenesis","scheme":"era"}],"scopus_subjects":["Health Sciences","Medicine","Life Sciences","Biochemistry, Genetics and Molecular Biology"],"startpage":"882","subjects":["neoplasms","hematology"],"title":"Which patients with myelofibrosis should receive ruxolitinib therapy? ELN-SIE evidence-based recommendations","type":"article","mendeley_url":"http:\/\/www.mendeley.com\/research\/patients-myelofibrosis-receive-ruxolitinib-therapy-elnsie-evidencebased-recommendations"},"altmetric_score":{"score":4.6,"score_history":{"1y":4.6,"6m":0.5,"3m":0,"1m":0,"1w":0,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":4.6},"context_for_score":{"all":{"total_number_of_other_articles":8088698,"mean":6.8825438942685,"rank":1652883,"this_scored_higher_than_pct":79,"this_scored_higher_than":6428516,"rank_type":"exact","sample_size":8088698,"percentile":79},"similar_age_3m":{"total_number_of_other_articles":244703,"mean":12.75510361174,"rank":69626,"this_scored_higher_than_pct":71,"this_scored_higher_than":174699,"rank_type":"exact","sample_size":244703,"percentile":71},"this_journal":{"total_number_of_other_articles":1811,"mean":5.2931425414365,"rank":489,"this_scored_higher_than_pct":72,"this_scored_higher_than":1316,"rank_type":"exact","sample_size":1811,"percentile":72},"similar_age_this_journal_3m":{"total_number_of_other_articles":80,"mean":9.4487848101266,"rank":30,"this_scored_higher_than_pct":61,"this_scored_higher_than":49,"rank_type":"exact","sample_size":80,"percentile":61}}},"demographics":{"poster_types":{"member_of_the_public":7,"researcher":1,"practitioner":2,"science_communicator":1},"users":{"twitter":{"cohorts":{"Scientists":1,"Practitioners (doctors, other healthcare professionals)":2,"Members of the public":7,"Science communicators (journalists, bloggers, editors)":1}},"mendeley":{"by_status":{"Professor > Associate Professor":2,"Student  > Master":1,"Other":1},"by_discipline":{"Medicine and Dentistry":3,"Unspecified":1}}},"geo":{"twitter":{"IN":1,"GB":1,"ES":2,"CA":1},"mendeley":{"SE":1}}},"posts":{"twitter":[{"url":"http:\/\/twitter.com\/KarenSweiss\/statuses\/788470783681163264","license":"gnip","citation_ids":[12736242],"posted_on":"2016-10-18T20:04:18+00:00","author":{"name":"Karen Sweiss","image":"https:\/\/pbs.twimg.com\/profile_images\/899816186808086528\/6vHwAO73_normal.jpg","description":"Clinical Pharmacist, Clinical Assistant Professor, Hematology and BMT, University of Illinois at Chicago","id_on_source":"KarenSweiss","tweeter_id":"397479698","geo":{"lt":null,"ln":null},"followers":575},"tweet_id":"788470783681163264"},{"url":"http:\/\/twitter.com\/satya_yadav\/statuses\/788563406085251072","license":"gnip","rt":["KarenSweiss"],"citation_ids":[12736242],"posted_on":"2016-10-19T02:12:21+00:00","author":{"name":"Satya Prakash Yadav","url":"https:\/\/scholar.google.co.in\/citations?user=ZBx2DK4AAAAJ&hl=en","image":"https:\/\/pbs.twimg.com\/profile_images\/821028432645484544\/8eqw00l2_normal.jpg","description":"Director, Pediatric Hematology Oncology & Bone Marrow Transplant, Medanta Hospital, Gurgaon, Haryana, India","id_on_source":"satya_yadav","tweeter_id":"113879784","geo":{"lt":28.4601,"ln":77.02635,"country":"IN"},"followers":861},"tweet_id":"788563406085251072"},{"url":"http:\/\/twitter.com\/GarbineLizeaga\/statuses\/788602287539232768","license":"gnip","rt":["KarenSweiss"],"citation_ids":[12736242],"posted_on":"2016-10-19T04:46:51+00:00","author":{"name":"Garbi\u00f1e Lizeaga","image":"https:\/\/pbs.twimg.com\/profile_images\/786651537573572608\/fOvQvTXd_normal.jpg","description":"FHyAP. OSI Donostialdea. De todo como en botica.","id_on_source":"GarbineLizeaga","tweeter_id":"2244183212","geo":{"lt":null,"ln":null},"followers":409},"tweet_id":"788602287539232768"},{"url":"http:\/\/twitter.com\/FarmaOnco\/statuses\/788613534875807744","license":"gnip","rt":["KarenSweiss"],"citation_ids":[12736242],"posted_on":"2016-10-19T05:31:33+00:00","author":{"name":"FarmaOnco","image":"https:\/\/pbs.twimg.com\/profile_images\/2930931336\/c5ed1efcf9ddf36d4803c1ab88604f4f_normal.jpeg","description":"Farmac\u00e9utica hospitalaria que intenta mantenerse al d\u00eda en onco, hemato y otras cosas","id_on_source":"FarmaOnco","tweeter_id":"917639060","geo":{"lt":null,"ln":null},"followers":1686},"tweet_id":"788613534875807744"},{"url":"http:\/\/twitter.com\/NatRevClinOncol\/statuses\/801768079352938496","license":"gnip","citation_ids":[12736242],"posted_on":"2016-11-24T12:43:00+00:00","author":{"name":"NatureRevClinOncol","url":"http:\/\/www.nature.com\/nrclinonc\/index.html","image":"https:\/\/pbs.twimg.com\/profile_images\/1587954262\/nrclinonc_Twitter_logo_normal.jpg","description":"The latest clinical diagnostic, treatment & personalized medicine advances & more from Nature Reviews Clinical Oncology, a reviews journal. Tweets by the eds.","id_on_source":"NatRevClinOncol","tweeter_id":"347276297","geo":{"lt":51.50853,"ln":-0.12574,"country":"GB"},"followers":10546},"tweet_id":"801768079352938496"},{"url":"http:\/\/twitter.com\/CancerWallonia\/statuses\/801777395036463104","license":"gnip","rt":["NatRevClinOncol"],"citation_ids":[12736242],"posted_on":"2016-11-24T13:20:01+00:00","author":{"name":"CancerWallonia","image":"https:\/\/pbs.twimg.com\/profile_images\/623178120615604224\/unGEOij0_normal.jpg","description":"Cancer: from Wallonia to the World, from the World to Wallonia -  Cancer: la Wallonie parle au Monde, le Monde parle \u00e0 la Wallonie","id_on_source":"CancerWallonia","tweeter_id":"2848852120","geo":{"lt":null,"ln":null},"followers":634},"tweet_id":"801777395036463104"},{"url":"http:\/\/twitter.com\/farmaSCQ\/statuses\/801778802296848384","license":"gnip","citation_ids":[12736242],"posted_on":"2016-11-24T13:25:37+00:00","author":{"name":"S Farmacia SCQ","image":"https:\/\/pbs.twimg.com\/profile_images\/830863833254215680\/RgyaT-Kr_normal.jpg","description":"Servicio de Farmacia Hospitalaria. Juntos ayudamos a mejorar la salud a trav\u00e9s de los medicamentos. Los pacientes primero.","id_on_source":"farmaSCQ","tweeter_id":"784324186734899200","geo":{"lt":42.88052,"ln":-8.54569,"country":"ES"},"followers":635},"tweet_id":"801778802296848384"},{"url":"http:\/\/twitter.com\/jai_mateo\/statuses\/801803177523900416","license":"gnip","rt":["farmaSCQ"],"citation_ids":[12736242],"posted_on":"2016-11-24T15:02:28+00:00","author":{"name":"Jaime Mateo","image":"https:\/\/pbs.twimg.com\/profile_images\/852579594196713472\/ncBnl2Xu_normal.jpg","description":"Especialista en Farmacia Hospitalaria. \nBuscando un lugar en el mundo...\nalways look on the bright side of life","id_on_source":"jai_mateo","tweeter_id":"2595305249","geo":{"lt":null,"ln":null},"followers":207},"tweet_id":"801803177523900416"},{"url":"http:\/\/twitter.com\/GarbineLizeaga\/statuses\/801807662069534720","license":"gnip","rt":["NatRevClinOncol"],"citation_ids":[12736242],"posted_on":"2016-11-24T15:20:18+00:00","author":{"name":"Garbi\u00f1e Lizeaga","image":"https:\/\/pbs.twimg.com\/profile_images\/786651537573572608\/fOvQvTXd_normal.jpg","description":"FHyAP. OSI Donostialdea. De todo como en botica.","id_on_source":"GarbineLizeaga","tweeter_id":"2244183212","geo":{"lt":null,"ln":null},"followers":409},"tweet_id":"801807662069534720"},{"url":"http:\/\/twitter.com\/elopmon\/statuses\/802109480741781504","license":"gnip","rt":["farmaSCQ"],"citation_ids":[12736242],"posted_on":"2016-11-25T11:19:37+00:00","author":{"name":"Elena L\u00f3pez","image":"https:\/\/pbs.twimg.com\/profile_images\/784833028736618496\/LhRbV-VK_normal.jpg","description":"Farmacia Hospitalaria. Onco-Hematology Pharmacist, BCOP. Santiago de Compostela.","id_on_source":"elopmon","tweeter_id":"255193326","geo":{"lt":42.88052,"ln":-8.54569,"country":"ES"},"followers":174},"tweet_id":"802109480741781504"},{"url":"http:\/\/twitter.com\/SCTNB\/statuses\/854992560913342464","license":"gnip","citation_ids":[12736242],"posted_on":"2017-04-20T09:38:06+00:00","author":{"name":"Dr T. Comeau , MD","image":"https:\/\/pbs.twimg.com\/profile_images\/378800000365246082\/373bc9bced36e8f90f0d52d727fc6b34_normal.jpeg","description":"Director New Brunswick Stem Cell Transplant Program ; SCT Physician ; #hematology: #leukemia, #MDS, #lymphoma, #mmsm , #apheresis, #bmtsm , #immunotherapy","id_on_source":"SCTNB","tweeter_id":"314498013","geo":{"lt":60.10867,"ln":-113.64258,"country":"CA"},"followers":1170},"tweet_id":"854992560913342464"},{"url":"http:\/\/twitter.com\/queizan\/statuses\/855817818562080769","license":"gnip","rt":["SCTNB"],"citation_ids":[12736242],"posted_on":"2017-04-22T16:17:22+00:00","author":{"name":"Dr. Jos\u00e9 A. Queiz\u00e1n","image":"https:\/\/pbs.twimg.com\/profile_images\/805313113016799232\/jBSTAjA7_normal.jpg","description":"Medico Especialista en Hematologia y Hemoterapia","id_on_source":"queizan","tweeter_id":"2334315479","geo":{"lt":null,"ln":null},"followers":403},"tweet_id":"855817818562080769"}]}}